OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and ...
OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and ...
Olanzapine ER is under clinical development by Teva Pharmaceutical Industries an...
MAS-825 is under clinical development by Novartis and currently in Phase II for ...
Olanzapine is under clinical development by Neurelis and currently in Phase I fo...
Omalizumab biosimilar is under clinical development by Teva Pharmaceutical Indus...
As Asda sets up a nationwide retail pharmacy in the UK and US grocer pharmacies ...
Precision immunology company Santa Ana Bio has announced a substantial funding i...
India-based Suven Pharmaceuticals has announced a definitive agreement to acquir...
AbbVie has made a licence agreement with FutureGen Biopharmaceutical for develop...
After a successful trial, the UK NHS has become the first to permanently adopt a...
If exercised, the option would allow Takeda to license the TKI olverembatinib ou...
England’s NHS has reported an 18% increase in the number of people with non-diab...
NPX-267 is under clinical development by NextPoint Therapeutics and currently in...
NPX-267 is under clinical development by NextPoint Therapeutics and currently in...
NPX-267 is under clinical development by NextPoint Therapeutics and currently in...
